NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Corcept ...

Corcept Therapeutics (CORT) announced the initiation of MOMENTUM, a clinical trial examining the prevalence of endogenous ...

After hours: March 19 at 5:04:42 PM EDT Loading Chart for CORT ...

For the year to December 2024, Corcept Therapeutics had an accrual ratio of -0.26. That implies it has very good cash conversion, and that its earnings in the last year actually significantly ...

Corcept Therapeutics Incorporated has a 1 year low of $20.84 and a 1 year high of $75.00. The company has a market cap of $5.80 billion, a P/E ratio of 43.65 and a beta of 0.61.

If you’re on the fence about investing in HUTCHMED (China) Limited or Corcept Therapeutics Incorporated because you’re not sure how they measure up, it’s important to compare them on a few factors ...

Corcept Therapeutics Trading Down 0.3 % Shares of NASDAQ:CORT opened at $54.85 on Friday. The stock has a 50 day moving average of $60.64 and a 200 day moving average of $52.72. The company has a ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Corcept Therapeutics Incorporated before investing. In this article, we go over a ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and ...